International, trade and IP
To secure its position as a life science superpower, the UK will need to increase its influence on the global stage by providing international leadership on issues of importance to the life science industry. Furthermore, it is vital that the UK鈥檚 domestic policies ensure that it can remain competitive versus other leading life science hubs.
To address the major health challenges of our time, the global pharmaceutical sector is pioneering cutting-edge science that can help develop new treatments and cures for diseases from cancer to dementia, as well as preventing disease through the latest generation of vaccines.
The fundamental role of IP for protecting and promoting UK scientific innovation and securing the UK’s ambition to be a life science super power
The UK’s international trading relationships with existing and future partners is fundamental to the continued success of the life sciences and sustainable, resilient supply of medicines for the NHS.
The UK is part of an increasingly competitive and changing global ecosystem. Regulatory regimes need to be dynamic and constantly evolving to adapt to the latest scientific and technological advances, as well as factors such as environmental sustainability and data privacy.
International, trade and IP publications
-
Facilitating trade in health products through international manufacturing recognition and harmonisation policy
The UK can bolster its position as a leader in life sciences by charting a pragmatic approach towards, and engaging purposefully with, a global recognition policy for manufacturing.
-
Building the UK’s international research collaborations
International research collaborations are fundamental to the discovery and early development of new medicines and vaccines.
-
Creating trade policy for a life sciences superpower
To achieve the Government’s ambition for the UK to thrive as a life sciences superpower, the Association of the British Pharmaceutical Industry (ABPI) believes the Government should establish three core pillars for its trade policy for pharmaceuticals.